Abstract
Mammary analogue secretory carcinoma (MASC) of the salivary gland is a newly-described,
rare, malignant tumour. Few patients present with MASC of the parotid gland, so the
exact characteristics, outcomes of treatment, and prognosis are unknown. The aim of
this study was to analyse the clinical features and outcomes of treatment of MASC
of the parotid gland in patients being treated at a single hospital. Five patients
with histopathologically-confirmed MASC of the parotid gland between January 2015
and August 2018 were retrospectively enrolled. In all cases preoperative fine-needle
aspiration cytology had failed to provide an accurate diagnosis. All patients underwent
a macroscopically complete oncological resection. Two patients had postoperative radiotherapy
(RT). On immunohistochemical examination all tumours stained for S-100 and mammaglobin
but not for DOG1. There were no regional recurrences or distant metastases in any
of the patients at their last follow-up. We obtained good results for patients with
MASC of the parotid gland with surgical treatment and postoperative RT.
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to British Journal of Oral and Maxillofacial SurgeryAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Mammary gland secretory carcinoma of salivary glands, containing the ETV6-NTRK3 fusion gene: a hitherto undescribed salivary gland tumor entity.Am J Surg Pathol. 2010; 34: 599-608
- Preservation of facial nerve with adjuvant radiotherapy for recurrent mammary analogue secretory carcinoma of parotid gland.J Craniofacial Surg. 2016; 27 (e364–6)
- Mammary analogue secretory carcinoma of salivary glands: diagnostic pitfall with distinct immunohistochemical profile and molecular features.Rare Tumors. 2017; 9: 7162
- Mammary analogue secretory carcinoma of the salivary glands: a diagnostic dilemma.Br J Oral Maxillofac Surg. 2017; 55: 290-292
- Systematic review of mammary analog secretory carcinoma of salivary glands at 7 years after description.Head Neck. 2017; 39: 1243-1248
- Mammary analogue secretory carcinoma of parotid: Is preoperative cytological diagnosis possible?.Diagn Cytopathol. 2016; 44: 519-525
- Clinicopathological characteristics and outcome of 31 patients with ETV6-NTRK3 fusion gene confirmed (mammary analogue) secretory carcinoma of salivary glands.Oral Oncol. 2018; 82: 29-33
- A systematic review including an additional pediatric case report: Pediatric cases of mammary analogue secretory carcinoma.Int J Pediatr Otorhinolaryngol. 2017; 100: 187-193
- Mammary analogue secretory carcinoma of the parotid gland in a pediatric patient.Otolaryngol Head Neck Surg. 2012; 146: 514-515
- Mammary analogue secretory carcinoma: update on a new diagnosis of salivary gland malignancy.Laryngoscope. 2014; 124: 188-195
- Cytopathological features of mammary analogue secretory carcinoma--review of literature.Diagn Cytopathol. 2015; 43: 131-137
Article info
Publication history
Published online: December 19, 2019
Identification
Copyright
© 2019 The British Association of Oral and Maxillofacial Surgeons. Published by Elsevier Ltd. All rights reserved.
